Mangalam Drugs and Organics Ltd
BSE:532637
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (0.7), the stock would be worth ₹35.84 (26% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | ₹28.35 |
0%
|
| 3-Year Average | 0.7 | ₹35.84 |
+26%
|
| 5-Year Average | 0.7 | ₹36.29 |
+28%
|
| Industry Average | 3.6 | ₹197.17 |
+595%
|
| Country Average | 2.9 | ₹155.73 |
+449%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Mangalam Drugs and Organics Ltd
BSE:532637
|
440m INR | 0.5 | -1.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 13.2 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 6 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 5.2 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 5.2 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 4.7 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 108.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4.1 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 3.2 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 3.1 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.9 |
| 70th Percentile | 5 |
| Max | 55 686.2 |
Other Multiples
Mangalam Drugs and Organics Ltd
Glance View
Mangalam Drugs & Organics Ltd. engages in the manufacture of drugs, medicines and allied products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-05-26. The firm handles marketing in both domestic and export markets. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. Its API products include Acyclovir, Amodiaquine HCI, Artemether, Artesunate, Atazanavir Sulfate, Atorvastatin Calcium, Bisoprolol Fumarate and Furosemide. Its intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine, 2-Dibutylamino-1-Ethanol (DBA), 4,7- Dichloroquinoline, Ortho Phenoxy Methane Sulfonanilide, Tenofovir Alafenamide Base and Tenofovir Disoproxil Base. The company also offers specialty chemicals, such a L (+)-Menthol, 2,3 Dihydrophthalazine-1,4-dione, 4-Cynoethyl-2- Methyl Phenol. The firm offers its products to Italy, Russia, China, Turkey, Nigeria, Uganda, Kenya and Pakistan. The company has two multi-product manufacturing facilities located at Vapi, district Valsad, Gujarat.
